Journal of Anesthesia

, 25:405

Reversible cerebral vasoconstriction syndrome with limb myoclonus following intravenous administration of methylergometrine

  • Tomoko Ishibashi
  • Satoru Ishibashi
  • Tokujiro Uchida
  • Koichi Nakazawa
  • Koshi Makita
Clinical Report


Neurological deficits associated with methylergometrine have been reported primarily as a result of reversible cerebral vasoconstriction syndromes (RCVS). RCVS are characterized by reversible multifocal vasoconstrictions of the cerebral arteries heralded by acute severe headache with or without neurological deficits. Here, we present the first case of suspected RCVS with transient limb myoclonus following the intravenous administration of methylergometrine during cesarean section. A 31-year-old woman who received slowly infused intravenous methylergometrine during a cesarean section suddenly reported severe occipital headache after 40 min, followed by apnea and unconsciousness for 8 min. A second administration of methylergometrine to treat the weakness of her uterine contractions resulted in a repeated loss of consciousness within minutes and the development of limb myoclonus. No abnormalities were detected by brain computerized tomography, magnetic resonance imaging, and electroencephalogram. She fully recovered spontaneously within 12 h. We consider that the transient limb myoclonus in our patient appeared as a result of RCVS caused by the intravenous administration of methylergometrine.


Limb myoclonus Methylergometrine Reversible cerebral vasoconstriction syndrome (RCVS) 


  1. 1.
    Williams TL, Lukovits TG, Harris BT, Harker Rhodes C. A fatal case of postpartum cerebral angiopathy with literature review. Arch Gynecol Obstet. 2007;275:67–77.PubMedCrossRefGoogle Scholar
  2. 2.
    Sekimoto E, Kunishige M, Kuriwaka R, Shinohara M, Ebisutani D, Kitamura K, Doi T, Kushiki N, Mitsui T. Delayed vasospasm in late postpartum cerebral angiopathy after withdrawal of methylergometrine. Cerebrovasc Dis. 2002;13:288–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Cassim F, Houdayer E. Neurophysiology of myoclonus. Neurophysiol Clin. 2006;36:281–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146:34–44.PubMedGoogle Scholar
  5. 5.
    de Labriolle A, Genée O, Heggs LM, Fauchier L. Acute myocardial infarction following oral methyl-ergometrine intake. Cardiovasc Toxicol. 2009;9:46–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Song JK, Fisher S, Seifert TD, Cacayorin ED, Alexandrov AV, Malkoff MD, Grotta JC, Campbell MS. Postpartum cerebral angiopathy: atypical features and treatment with intracranial balloon angioplasty. Neuroradiology. 2004;46:1022–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Ursell MR, Marras CL, Farb R, Rowed DW, Black SE, Perry JR. Recurrent intracranial hemorrhage due to postpartum cerebral angiopathy: implications for management. Stroke. 1998;29:1995–8.PubMedGoogle Scholar
  8. 8.
    de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56:523–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Yoshikawa H, Takamori M. Benign segmental myoclonus: electrophysiological evidence of transient dysfunction in the brainstem. J Clin Neurosci. 2001;8:54–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Dyer RA, van Dyk D, Dresner A. The use of uterotonic drugs during caesarean section. Int J Obstet Anesth. 2010;19:313–9.PubMedCrossRefGoogle Scholar
  11. 11.
    MacLennan SJ, Martin GR. Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:120–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogozo JM. Reversible cerebral arteriopathy associated with the administration of ergot derivatives. Cephalalgia. 1984;4:171–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bogousslavsky J, Despland PA, Regli F, Dubuis PY. Postpartum cerebral angiopathy: reversible vasoconstriction assessed by transcranial Doppler ultrasounds. Eur Neurol. 1989;29:102–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Sato S, Shimizu M, Endo K, Homma M, Yamamoto T. Postpartum cerebral angiopathy—a case report the vasculopathy associated with co-administration of two vasoconstrictives, methylergometrine maleate and sumatriptan (in Japanese with English abstract). Rinsho Shinkeigaku (Clin Neurol). 2004;44:96–101.Google Scholar
  15. 15.
    Nishiyama S, Yamamuro O, Kato N, Kurauchi O, Chaya J, Ono Y. Postpartum cerebral angiopathy due to methylergometrine maleate use. A case report (in Japanese with English abstract). Nippon Shusanki Shinseiji Igakukai Zasshi (Jpn J Perinatal Neonatal Med). 2006;42:101–4.Google Scholar

Copyright information

© Japanese Society of Anesthesiologists 2011

Authors and Affiliations

  • Tomoko Ishibashi
    • 1
  • Satoru Ishibashi
    • 2
  • Tokujiro Uchida
    • 1
  • Koichi Nakazawa
    • 1
  • Koshi Makita
    • 1
  1. 1.Department of Anesthesiology, Graduate School of MedicineTokyo Medical and Dental UniversityBunkyo-ku, TokyoJapan
  2. 2.Department of Neurology and Neurological Science, Graduate School of MedicineTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations